VINCRISTINE SULFATE
Embryonal Rhabdomyosarcoma
Children's Oncology GroupSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Embryonal Rhabdomyosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Children's Oncology Group | Phase 3 | B |
Vinorelbine Children's Oncology Group | Phase 3 | B |
DACTINOMYCIN Children's Oncology Group | Phase 3 | B |
Ixabepilone National Cancer Institute (NCI) | Phase 2 | B |
Rhil-7 National Cancer Institute (NCI) | Phase 1/2 | CCC |
Allogeneic Tumour Lysate National Cancer Institute (NCI) | Phase 1/2 | CCC |
Klh-Pulsed Autologous Dendritic Cell Vaccine National Cancer Institute (NCI) | Phase 1/2 | CCC |
Same molecule, other indications
VINCRISTINE SULFATE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →